United States: M&A/Private Equity

Business development companies (BDCs) have become a critical financing source for private equity-backed small- and middle-market companies while offering investors attractive private credit exposure. As the BDC market matures, sponsors and investors are increasingly exploring alternative structures, joint ventures with institutional investors, and evolving co-investment arrangements. The regulatory landscape continues to shift with proposed SEC rulemakings that could expand retail access to private markets

In a selective market, the most successful exits are the ones with clear preparation, starting at the initial investment, to build a credible value creation story.

Private equity investment in MedTech is surging through carve-outs and take-private deals, with average transaction values more than doubling as investors target innovative businesses with strong growth prospects. However, navigating FDA regulatory shifts, AI device oversight, and evolving healthcare delivery models requires disciplined diligence to separate genuine opportunities from hidden operational and compliance risks.